Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial (vol 36, pg 2508, 2013)

被引：0
|
作者：
Schernthaner, G.
机构：
来源：
DIABETES CARE | 2013年 / 36卷 / 12期
关键词：
D O I：
10.2337/dc13-er12b
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4172 / 4172
页数：1
相关论文
共 50 条
  • [1] Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
    Schernthaner, Guntram
    Gross, Jorge L.
    Rosenstock, Julio
    Guarisco, Michael
    Fu, Min
    Yee, Jacqueline
    Kawaguchi, Masato
    Canovatchel, William
    Meininger, Gary
    DIABETES CARE, 2013, 36 (09) : 2508 - 2515
  • [2] A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study
    Kitazawa, Masaru
    Katagiri, Takashi
    Suzuki, Hiromi
    Matsunaga, Satoshi
    Yamada, Mayuko
    Ikarashi, Tomoo
    Yamamoto, Masahiko
    Furukawa, Kazuo
    Iwanaga, Midori
    Hatta, Mariko
    Fujihara, Kazuya
    Yamada, Takaho
    Tanaka, Shiro
    Sone, Hirohito
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 811 - 821
  • [3] Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
    Nauck, Michael A.
    Del Prato, Stefano
    Meier, Juris J.
    Duran-Garcia, Santiago
    Rohwedder, Katja
    Elze, Martina
    Parikh, Shamik J.
    DIABETES CARE, 2011, 34 (09) : 2015 - 2022
  • [4] Assessment of Glycemic Variability during Treatment with Sitagliptin Compared with Placebo in Patients with Diabetes Type 2 without Adequate Glycemic Control on Metformin Background
    Butaeva, Svetlana
    Ametov, Alexander
    DIABETES, 2017, 66 : A331 - A331
  • [5] Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus
    Yale, Jean-Francois
    Xie, John
    Sherman, Stephen E.
    Garceau, Claude
    CLINICAL THERAPEUTICS, 2017, 39 (11) : 2230 - 2242
  • [6] A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
    Moses, Robert G.
    Round, Elizabeth
    Shentu, Yue
    Golm, Gregory T.
    O'Neill, Edward A.
    Gantz, Ira
    Engel, Samuel S.
    Kaufman, Keith D.
    Goldstein, Barry J.
    JOURNAL OF DIABETES, 2016, 8 (05) : 701 - 711
  • [7] Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. A randomized, 52-week, double-blind, active-controlled noninferiority trial
    Nauck, M.
    del Prato, S.
    Meier, J. J.
    Duran-Garcia, S.
    Rohwedder, K.
    Elze, M.
    Parikh, S. J.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 : S6 - S15
  • [8] Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
    Pratley, Richard E.
    Nauck, Michael
    Bailey, Timothy
    Montanya, Eduard
    Cuddihy, Robert
    Filetti, Sebastiano
    Thomsen, Anne Bloch
    Sondergaard, Rie Elvang
    Davies, Melanie
    LANCET, 2010, 375 (9724): : 1447 - 1456
  • [9] Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. (vol 375, pg 1447, 2010)
    Pratley, R. E.
    Nauck, M.
    Bailey, T.
    LANCET, 2010, 376 (9737): : 234 - 234
  • [10] Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
    Handelsman, Yehuda
    Mathieu, Chantal
    Del Prato, Stefano
    Johnsson, Eva
    Kurlyandskaya, Raisa
    Iqbal, Nayyar
    Garcia-Sanchez, Ricardo
    Rosenstock, Julio
    DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 883 - 892
12345